Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention-Reference-Cited by-同舟云学术

Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention

Published:2016 Issue:19 Volume:55 Page:2759-2764
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Masuda Takahiro¹,Murakami Takuya¹,Igarashi Yusuke¹,Okabe Kyochika¹,Kobayashi Takahisa¹,Takeda Shin-ichi¹,Saito Takako²,Sekiguchi Chuji³,Miyazawa Yasuharu³,Akimoto Tetsu¹,Saito Osamu¹,Muto Shigeaki¹,Nagata Daisuke¹

Affiliation:

1. Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan

2. Kawashima Naika Clinic, Japan

3. Nasu Minami Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/55/19/55_55.7133/_pdf

Reference34 articles.

1. 1. Tsai YC, Tsai JC, Chen SC, et al. Association of fluid overload with kidney disease progression in advanced CKD: a prospective cohort study. Am J Kidney Dis 63: 68-75, 2014.

2. 2. Tsai YC, Chiu YW, Tsai JC, et al. Association of fluid overload with cardiovascular morbidity and all-cause mortality in stages 4 and 5 CKD. Clin J Am Soc Nephrol 10: 39-46, 2015.

3. 3. Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 292: 288-294, 2000.

4. 4. Cleland JG, Coletta A, Witte K. Practical applications of intravenous diuretic therapy in decompensated heart failure. Am J Med 119: S26-S36, 2006.

5. 5. Goldsmith SR, Bart BA, Burnett J. Decongestive therapy and renal function in acute heart failure: time for a new approach? Circ Heart Fail 7: 531-535, 2014.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical efficacy of tolvaptan in acute decompensated heart failure patients with severe aortic stenosis and atrial fibrillation: a sub-analysis from the LOHAS registry;Heart and Vessels;2024-05-07

2. Renal ultrasonography predicts worsening renal function in patients with heart failure under tolvaptan administration;ESC Heart Failure;2024-03-12

3. The characteristics and outcomes in patients with acute heart failure who used tolvaptan: from KCHF registry;ESC Heart Failure;2023-08-29

4. Tolvaptan Reduces Extracellular Fluid per Amount of Body Fluid Reduction Less Markedly than Conventional Diuretics;Internal Medicine;2022-09-01

5. Therapeutic Potential of a Vasopressin V2 Receptor Antagonist for Calcium Channel Blocker-Associated Edema with Vasospastic Angina;Case Reports in Cardiology;2022-07-08